Optimal treatment for recurrent/metastatic head and neck cancer
Jan B. Vermorken,Pol Specenier +1 more
TLDR
A recent European randomized trial showed that adding cetuximab, the first clinically available EGFR-directed monoclonal antibody, to a standard chemotherapy regimen (platinum/5-fluorouracil) leads to an important survival benefit and this, with support of an additional smaller study in the US, has changed practice.About:
This article is published in Annals of Oncology.The article was published on 2010-10-01 and is currently open access. It has received 343 citations till now. The article focuses on the topics: Combination chemotherapy & Chemotherapy regimen.read more
Citations
More filters
Journal ArticleDOI
Head and Neck Cancer
TL;DR: A large number of head and neck cancers are now related to human papillomavirus infection rather than tobacco and alcohol, and the number of cases is expected to increase in the coming years.
Book ChapterDOI
Head and Neck Tumours
B. Spiessl,O. Scheibe,G. Wagner +2 more
TL;DR: A number of clinical trials of targeted therapies in HNSCC show promise in the control of both advanced loco-regional disease and relapsed/metastatic disease.
Journal ArticleDOI
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Lillian L. Siu,Caroline Even,Ricard Mesia,Éva Remenár,Amaury Daste,Jean Pierre Delord,Jürgen Krauss,Nabil F. Saba,Lisle Nabell,Neal Ready,Irene Brana,Nuria Kotecki,Dan P. Zandberg,Jill Gilbert,Hisham Mehanna,Marcelo Bonomi,Anthony Jarkowski,Anthony Jarkowski,Giovanni Melillo,Jon Armstrong,Sophie Wildsmith,Jérôme Fayette +21 more
TL;DR: In patients with R/M HNSCC and low or no PD-L1 tumor cell expression, all 3 regimens exhibited a manageable toxicity profile and Durvalumab and durvalumAB + tremelimumab resulted in clinical benefit, with minimal observed difference between the two.
Journal ArticleDOI
The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck.
TL;DR: This review will explore what is known about the interactions between PD-1 and PD-L1, with a focus on SCCHN, and specifically discuss how this pathway can be manipulated with therapeutic intent.
Journal ArticleDOI
High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.
Yueh Min Lin,Wen-Wei Sung,Ming-Ju Hsieh,Shih Chen Tsai,Hung Wen Lai,Shu Mei Yang,Ko Hong Shen,Mu Kuan Chen,Huei Lee,Kun Tu Yeh,Chih-Jung Chen +10 more
TL;DR: It is suggested that PD-L1 expression, determined by IHC staining, could be an independent prognostic marker for OSCC patients who are male or who have a smoking habit.
References
More filters
Book
Cancer : Principles and Practice of Oncology
TL;DR: Part I: Molecular Biology of Cancer Molecular Methods in Oncology Section 1. Amplification Techniques Section 2. RNA Interference Section 3. cDNA arrays Section 4. Tissue arrays Section 5. Cytogenetics Section 6. Bioinformatics Genomics and Proteomics Molecular Targets in oncology.
Journal ArticleDOI
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Jan B. Vermorken,Ricard Mesia,Fernando Rivera,Eva Remenar,Andrzej Kawecki,Sylvie Rottey,Jozsef Erfan,Dmytro Zabolotnyy,Heinz Roland Kienzer,Didier Cupissol,Frederic Peyrade,Marco Benasso,Ihor Vynnychenko,Dominique De Raucourt,Carsten Bokemeyer,Armin Schueler,Nadia Amellal,Ricardo Hitt +17 more
TL;DR: Adding cetuximab to platinum-based chemotherapy with fluorouracil (platinum-fluorouracils) significantly prolonged the median overall survival and improved overall survival when given as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck.
Journal ArticleDOI
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Marshall R. Posner,Diane Hershock,Cesar R. Blajman,Elizabeth Mickiewicz,Eric Winquist,Vera Gorbounova,Sergei Tjulandin,Dong M. Shin,Kevin J. Cullen,Thomas J. Ervin,Barbara A. Murphy,Luis E. Raez,Roger B. Cohen,Monica Spaulding,Roy B. Tishler,Berta Roth,Rosana del Carmen Viroglio,Varagur Venkatesan,Ilya Romanov,Sanjiv S. Agarwala,K. William Harter,Matthew Dugan,Anthony J. Cmelak,Arnold M. Markoe,Paul W. Read,Lynn Steinbrenner,A. Dimitrios Colevas,Charles M. Norris,Robert I. Haddad +28 more
TL;DR: Patients with squamous-cell carcinoma of the head and neck who received docetaxel plus cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy had a significantly longer survival than did patients who received cisPlatin and fluoride induction chemotherapyplus cheMoradiotherapy.
Journal ArticleDOI
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Jan B. Vermorken,Eva Remenar,Carla M.L. van Herpen,Thierry Gorlia,Ricard Mesia,M. Degardin,John S. Stewart,Svetislav Jelic,Jan Betka,Joachim H. Preiss,Danielle Van den Weyngaert,Ahmad Awada,Didier Cupissol,Heinz Roland Kienzer,Augustin Rey,Isabelle Desaunois,Jacques Bernier,Jean-Louis Lefebvre +17 more
TL;DR: Induction chemotherapy with the addition of docetaxel significantly improved progression-free and overall survival in patients with unresectable squamous-cell carcinoma of the head and neck.
Journal ArticleDOI
Head and neck cancer.
TL;DR: There have been important advances in understanding of the molecular pathogenesis and progression of head and neck cancer and also in approaches to therapy, which include innovations in surgery, radiation therapy, and cytotoxic-drug therapy.